April 27, 2023 by admin aurigene Discovery of orally bioavailable SMARCA2/4 dual degraders for treatment of acute myeloid leukemia
April 27, 2023 by admin aurigene An orally bioavailable small molecule dual antagonist of TIGIT and PD-L1 pathways shows immune-mediated anti-tumor activity
April 27, 2023 by admin aurigene Oral Immune Checkpoint Antagonists Dually Targeting TIGIT and PD-1 pathways for Cancer Therapy
April 27, 2023 by admin aurigene Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers
April 27, 2023 by admin aurigene Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers
April 27, 2023 by admin aurigene Novel inhibitors of protein arginine methyltransferase 5 (PRMT5) for the treatment of solid tumors
April 27, 2023 by admin aurigene Preclinical in vivo evaluation of efficacy, pharmacokinetics and pharmacodynamics of novel PRMT5 inhibitors in multiple tumor models (PRMT5i)
April 27, 2023 by admin aurigene Targeting CD47- SIRPα interaction by novel peptide-based antagonists
